Estimating Long Term Cost Savings from Treatment of Alzheimer’s DiseaseA Modelling Approach

被引：0
|
作者：
Paul Fenn
Alastair Gray
机构：
[1] University of Nottingham,The Business School
[2] Oxford Health Economics Research Centre,undefined
来源：
PharmacoEconomics | 1999年 / 16卷
关键词：
Adis International Limited; Rivastigmine; Tacrine; Baseline Severity; Weibull Shape Parameter;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: This paper puts forward a proposal for a modelling approach to the estimation of long term cost savings from the treatment of Alzheimer’s disease(AD).
引用
收藏
页码：165 / 174
页数：9
相关论文
共 50 条
  • [21] Long-term treatment of Alzheimer's disease with idebenone
    Gutzmann, H
    Hadler, D
    Erzigkeit, H
    ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, 1997, : 687 - 705
  • [22] Long-term effects of Alzheimer's disease treatment
    Wimo, Anders
    LANCET NEUROLOGY, 2015, 14 (12): : 1145 - 1146
  • [23] Metrifonate in the long-term treatment of Alzheimer's disease
    Cyrus, PA
    Ruzicka, B
    Gulanski, B
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1998, 46 (09) : S35 - S35
  • [24] Long-term tacrine treatment in Alzheimer's disease
    Farre, M
    Roset, PN
    LANCET, 1996, 348 (9035): : 1181 - 1182
  • [25] Current and Emerging Drug Treatment Options for Alzheimer’s DiseaseA Systematic Review
    Nathan Herrmann
    Sarah A. Chau
    Ida Kircanski
    Krista L. Lanctôt
    Drugs, 2011, 71 : 2031 - 2065
  • [26] Long-term effects of Alzheimer's disease treatment
    Atri, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 661 - 661
  • [27] Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s DiseaseA UK Evaluation Using Discrete-Event Simulation
    Denis Getsios
    Steve Blume
    K. Jack Ishak
    Grant D. H. Maclaine
    PharmacoEconomics, 2010, 28 : 411 - 427
  • [28] Audit of Long Term Oxygen Prescribing Results in Cost Savings
    Cheng, R.
    Davis, P.
    Shelly, S.
    Kennedy, R.
    Korn, B.
    Nyambe, N.
    O'Donnell, R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2013, 182 : S443 - S443
  • [29] Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s DiseaseA Markov Model in Finland
    Clément François
    Harri Sintonen
    Raimo Sulkava
    Benoît Rive
    Clinical Drug Investigation, 2004, 24 : 373 - 384
  • [30] Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment
    Jun, H.
    Shi, Z.
    Mattke, Soeren
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2023, 11 (01): : 179 - 184
12345